ArticleYonago acta medica2026
Establishment and Characterization of Canine Malignant Mesothelioma Cells.
Article in Yonago acta medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We established persistently passable canine malignant mesothelioma (cMM) cell lines from tumor samples obtained from affected dogs, analyzed their characteristics, and investigated their sensitivity to anticancer drugs and photodynamic therapy (PDT) using 5-aminolevulinic acid hydrochloride (5-ALA). Methods: Histopathological analyses were performed on SDK cells cultured under two-dimensional (2D) and three-dimensional (3D) conditions, as well as on tumor tissues derived from SDK cells. Cell proliferation in both culture systems and sensitivity to anticancer agents and PDT were assessed. Results: In 2D culture, SDK cells appeared round to polygonal, with marked variability in size and the presence of pyknotic nuclei. In 3D culture, both large and small cells formed loose clusters with scattered cellular processes. Following subcutaneous transplantation into mice, tumor masses exhibited nodular lesions composed of tumor cells and fibroblasts. Cytokeratin expression was prominent in 3D-cultured cells and tumor tissues but weak in 2D-cultured cells. Vimentin and calretinin were expressed in all cells. SDK cells showed minimal sensitivity to carboplatin but were sensitive to doxorubicin. Notably, SDK cells were also sensitive to 5-ALA-mediated PDT. Conclusion: SDK cells may serve as a novel cell line for elucidating the pathogenesis of cMM and for developing new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.